0001104659-21-013180.txt : 20210205 0001104659-21-013180.hdr.sgml : 20210205 20210205201641 ACCESSION NUMBER: 0001104659-21-013180 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210204 FILED AS OF DATE: 20210205 DATE AS OF CHANGE: 20210205 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Oliviero James F III CENTRAL INDEX KEY: 0001434718 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38128 FILM NUMBER: 21598224 MAIL ADDRESS: STREET 1: C/O KERYX BIOPHARMACEUTICALS, INC. STREET 2: 750 LEXINGTON AVENUE CITY: NEW YORK STATE: NY ZIP: 10022 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Checkpoint Therapeutics, Inc. CENTRAL INDEX KEY: 0001651407 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 472568632 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2 GANSEVOORT STREET STREET 2: 9TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10014 BUSINESS PHONE: 212-554-4366 MAIL ADDRESS: STREET 1: 2 GANSEVOORT STREET STREET 2: 9TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10014 4 1 tm215541-2_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2021-02-04 0 0001651407 Checkpoint Therapeutics, Inc. CKPT 0001434718 Oliviero James F III 2 GANSEVOORT ST, 9TH FLOOR NEW YORK NY 10014 1 1 0 0 CEO, President and Director COMMON STOCK 2021-02-04 4 S 0 70000 3.5075 D 3202000 D COMMON STOCK 2021-02-05 4 S 0 48790 3.4176 D 3153210 D In connection with the vesting of 243,750 shares, these shares were sold by the Company's restricted stock administrator in order to satisfy Mr. Oliviero's tax withholding obligations. Mr. Oliviero had no discretion with respect to such sale, which was transacted by the Company in accordance with the Company's corporate policies regarding the vesting of restricted stock. Represents the weighted average price of the shares sold in this transaction. The range of prices for such transaction was $3.50 to $3.525. The reporting person undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. Represents the weighted average price of the shares sold in this transaction. The range of prices for such transaction was $3.35 to $3.52. The reporting person undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. Includes shares of restricted Common Stock, which vest over various time periods /s/ James F. Oliviero, III 2021-02-05